NeoPhore Ltd
Discovering drugs that create neoantigens
18 employees · est. 2017 · Cambridge, United Kingdom
Trillium Therapeutics Inc.
Clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer.
14 employees · est. 2004 · Cambridge, United States
Trillium Therapeutics Inc. is the older company (2017 vs 2004).
Side-by-Side Comparison
| Metric | NeoPhore Ltd | Trillium Therapeutics Inc. |
|---|---|---|
| Founded | ||
| Founded | 2017 | 2004 older |
| Headquarters | ||
| Headquarters | Cambridge, United Kingdom | Cambridge, United States |
| Employees | ||
| Employees | 18 | 14 |
| Industry | ||
| Industry | Biotechnology, Health and Wellness | Biopharma, Biotechnology, Health Care |
| Funding Stage | ||
| Funding Stage | Series B | Post Ipo Equity |
| Total Funding | ||
| Total Funding | $33.80M | $281.98M |
| Funding Rounds | ||
| Funding Rounds | 6 | 9 |
| Services | ||
| Services | Not tracked yet | Not tracked yet |
| Target Customers | ||
| Target Customers | Not tracked yet | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Immuno-oncology, Small Molecule Therapeutics, Neoantigen Creation, Genetic Mechanisms, Cancer Immunotherapy, Immune System Stimulation, Cancer Treatment, Drug Development, Cancer Therapy, Clinical Validation, Lab Studies, Oncology, Drug Targeting, Patient Outcomes, Cancer Research | Immuno-oncology, Therapies, Cancer Treatment, CD47, Immune System, Decoy Receptors, Tumor Cells, Clinical Stage, Immunotherapy, Cancer Research |
| Website | ||
| Website | neophore.com | trilliumtherapeutics.com |
About NeoPhore Ltd
NeoPhore Ltd is a biotechnology startup headquartered in the United Kingdom, founded in 2017. The company's focus is on creating novel small molecule immuno-oncology therapeutics. Their drugs target genetic mechanisms that have been validated in both clinical and lab studies for promoting neoantigen...
About Trillium Therapeutics Inc.
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company focused on developing innovative therapies for the treatment of cancer. With a strong emphasis on CD47, a molecule commonly utilized by tumors to evade the immune system, Trillium aims to combat this protective "do not eat" signa...
Be first to know when either one moves
Funding rounds, hiring surges, leadership changes and stack switches at NeoPhore Ltd and Trillium Therapeutics Inc. — tracked continuously, sent the day they land.
Funding, hiring, leadership and stack changes at NeoPhore Ltd and Trillium Therapeutics... — by email.
Frequently Asked Questions
Compare NeoPhore Ltd with someone else
Start typing a company name or domain.